Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea

Clinical Cancer Research

Volumn 5, Issue 4, 1999, Pages 747-751

  Nieto, Yago ^a   Xu, Xuesheng ^a   Cagnoni, Pablo J ^a   Matthes, Steve ^a   Shpall, Elizabeth J ^a   Bearman, Scott I ^a   Murphy, James ^a   Jones, Roy B ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE;

AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ACTIVATION; DRUG INACTIVATION; DRUG MONITORING; HODGKIN DISEASE; HUMAN; INDIVIDUALITY; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PREDICTION; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BREAST NEOPLASMS; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 0032905310     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Grochow, L. B., Piantadosi, S., Santos, G., and Jones, R. Busulfan dose adjustment decreases the risk of venoocclusive disease in patients undergoing bone marrow transplantation. Proc. Am. Assoc. Cancer Res., 33: 200, 1992.
2. Demirer, T., Buckner, C. D., Appelbaum, F. R., Bensinger, W. I., Sanders, J., Lambert, K., Clift, R., Fefer, A., Storb, R., and Slattery J. T. Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: Phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplant., 17: 491-495, 1996.
3. Evans, W. E., Relling, M. V., Rodman, J. H., Crom, W. R., Boyett, J. M., and Pui, C. H. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N. Engl. J. Med., 338: 499-505, 1998.
4. Ayash, L. J., Wright, J. E., Tretyakov, O., Gonin, R., Elias, A., Wheeler, C., Eder, J. P., Rosowsky, A., Antman, K., and Frei, E., III. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J. Clin. Oncol., 10: 995-1000, 1992.
5. Peters, W. P., Eder, J. P., Henner, W. D., Schryber, S., Wilmore, D., Finberg, R., Schoenfeld, D., Bast, R., Gargone, B., Antman, K., and Frei, E., III. High-dose combination alkylating agents with autologous bone marrow support: a Phase I trial. J. Clin. Oncol., 4: 646-654, 1986.
6. El-Yazigi, A., and Martin, C. Improved analysis of cyclophosphamide by capillary gas chromatography with thermionic (nitrogen-phosphorus) detection and silica sample purification. J. Chromatogr., 374: 177-182, 1986.
7. Tew, K. D., Colvin, M., and Chabner, B. A. Alkylating agents. In: B. A. Chabner and D. L. Longo (eds.), Cancer Chemotherapy and Biotherapy, Ed. 2. pp. 297-332. Philadelphia: Lippincott-Raven, 1996.
8. Slattery, J. T., Kalhorn, T. F., McDonald, G. B., Lambert, K., Buckner, C. D., Bensinger, W. I., Anasetti, C., and Appelbaum, F. R. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J. Clin. Oncol., 14: 1484-1494, 1996.
9. LeBlanc, G. A., Sundseth, S. S., Weber, G. F., and Waxman, D. J. Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats. Cancer Res., 52: 540-547, 1992.
10. Cagnoni, P. J., Matthes, S., Dufton, C., Shpall, E. J., Bearman, S. I., Purdy, M. H., Day, T., and Jones, R. B. Ondansetron significantly reduces the area under the curve (AUC) of cyclophosphamide (CPA) and cisplatin (cDDP). Proc. Am. Soc. Clin. Oncol., 14: 462, 1995.
11. Yule, S. M., Boddy, A. V., Cole, M., Price, L., Wyllie, R., Tasso, M. J., Pearson, A. D., and Idle, J. R. Cyclophosphamide pharmacokinetics in children. Br. J. Clin. Pharmacol., 41: 13-19, 1996.
12. Grochow, L. B., and Colvin, O. M. Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet., 4: 380-394, 1980.
13. Chen T-L., Passos-Coelho, J. L., Noe, D. A., Kennedy, M. J., Black, K. C., Colvin, O. M., and Grochow, L. B. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res., 55: 810-816, 1995.
14. Chen T-L., Kennedy, M. J., Anderson, L. W., Kiraly, S. B., Black, K. C., Colvin, O. M., and Grochow, L. B. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Drug Metab. Dispos., 25: 544-551, 1997.
15. Bagley, C. M., Jr., Botick, F. W., and De Vita, V. T., Jr. Clinical pharmacology of cyclophosphamide. Cancer Res., 33: 226-233, 1973.
16. Graham, M. I., Shaw, I. C., Souhami, R. L., Sidau, B., Harper, P. G., and McLean, A. E. Decreased plasma half-life of cyclophosphamide during repeated high-dose administration. Cancer Chemother. Pharmacol., 10: 192-193, 1983.
17. Sladek, N. E., Priest, J., Doeden, D., Mirocha, C. J., Pathre, S., and Krivit, W. Plasma half-life and urinary excretion of cyclophosphamide in children. Cancer Treat. Rep., 64: 1061-1066, 1980.
18. Sladek, N. E., Doeden, D., Powers, J. F., and Krivit, W. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Treat. Rep., 68: 1247-1254, 1984.
19. Anderson, L. W., Ludeman, S. M., Colvin, O. M., Grochow, L. B., and Strong, J. M. Quantitation of 4-hydroxycyclophosphamide/aldophosphamide in whole blood. J. Chromatogr. B, 667: 247-257, 1995.
20. Ludeman, S. M., Shulamn-Roskes, E. M., Wong, K. K., Han, S. Y., Anderson, L. W., Strong, J. M., and Colvin, O. M. Oxime derivatives of the intermediary oncostatic metabolites of cyclophosphamide and ifosfamide: synthesis and deuterium labeling for applications to metabolite quantification. J. Pharmacol. Sci., 84: 393-398, 1995.
21. Busse, D., Busch, F. W., Bohnenstengel, F., Eichelbaum, M., Fischer, P., Opalinska, J., Schumacher, K., Schweizer, E., and Kroemer, H. K. Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism. J. Clin. Oncol., 15: 1885-1896, 1997.
22. Dockham, P. A., Sreerama, L., and Sladek, N. E. Relative contribution of human erythrocyte aldehyde dehydrogenase to the systemic detoxification of the oxazaphosphorines. Drug Metab. Dispos., 25: 1436-1441, 1997.